European Journal of Clinical Microbiology

, Volume 4, Issue 2, pp 144–145 | Cite as

Interpretive standards of cefbuperazone disk diffusion susceptibility tests

  • A. L. Barry
  • R. N. Jones
  • C. Thornsberry


Internal Medicine Susceptibility Test Disk Diffusion Disk Diffusion Susceptibility Diffusion Susceptibility Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kumano, K., Mikami, H., Inoue, M., Mitsuhashi, S.: In vitro and in vivo antibacterial activity of T-1982. Chemotherapy 1982, 30, Supplement: 1–19.Google Scholar
  2. 2.
    Tai, M., Fukuoka, Y., Yotsuji, A., Kumano, K., Takahata, M., Mikami, H., Yasuda, T., Saikawa, I., Mitsuhashi, S.: In vitro and in vivo antibacterial activity of T-1982, a new semisynthetic cephamycin antibiotic. Antimicrobial Agents and Chemotherapy 1982, 22: 724–728.Google Scholar
  3. 3.
    Khan, N. J., Bihl, J. A., Schell, R. F., LeFrock, J. L., Weber, S. J.: Antimicrobial activities of BMY-28142, cefbuperazone, and cefpiramide compared with those of other cephalosporins. Antimicrobial Agents and Chemotherapy 1984, 26: 585–590.PubMedGoogle Scholar
  4. 4.
    National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved Standard M2-A3. NCCLS, Villanova, PA, 1984.Google Scholar
  5. 5.
    National Committee for Clinical Laboratory Standards: Standard methods for dilution antimicrobial susceptibility tests for bacteria that grows aerobically. Tentative standard M7-T. NCCLS, Villanova, PA, 1982.Google Scholar

Copyright information

© Vieweg Publishing 1985

Authors and Affiliations

  • A. L. Barry
    • 1
  • R. N. Jones
    • 2
  • C. Thornsberry
    • 3
  1. 1.Clinical Microbiology InstituteTualatinUSA
  2. 2.Kaiser-Permanente Regional LaboratoryClackamasUSA
  3. 3.Centers for Disease ControlAtlantaUSA

Personalised recommendations